Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05984953 · ClinicalTrials.gov registry record
Rosuvastatin and Evolocumab for Coronary Artery Disease
A clinical trial, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- 195
- Enrollment target
NCT05984953: Completed study, sponsored by Icahn School of Medicine at Mount Sinai.
NCT05984953 is a clinical trial that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 195 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05984953 has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- 195 participants
- Enrollment target
Study Summary
The aim of the retrospective study is to characterize the molecular mechanisms responsible for the effect of statins and evolocumab in patients with stable coronary artery disease. The research team will retrieve and review intravascular imaging and gene expression data previously collected in the catheterization laboratory during the following time-period: 8/1/2013-4/14/2015 and 5/4/2021 - 10/28/2022.
Primary Outcome
Expression levels of mRNA in blood cells of the patients to be measured to identify the genes which are associated with a beneficial response to treatment using transcriptomic analysis of PBMC to find the key genes (biomarkers) responsible for effective therapy.
Interventions
- DRUG statin
- DRUG evolocumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2013-08-01 |
| Est. Completion | 2022-10-28 |
What the finished NCT05984953 record still lists
NCT05984953 is an observational study that tracks outcomes without assigning an intervention. The registered 195 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which statin is the first listed.
NCT05984953 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05984953 about?
NCT05984953 is a clinical study titled "Rosuvastatin and Evolocumab for Coronary Artery Disease". The aim of the retrospective study is to characterize the molecular mechanisms responsible for the effect of statins and evolocumab in patients with stable coronary artery disease. The research team will retrieve and review intravascular imaging and gene expression data previously collected in the c...
What is the current status of trial NCT05984953?
This trial is currently completed. The enrollment target is 195 participants. The study started on 2013-08-01. Estimated completion is 2022-10-28.
What interventions are being tested in trial NCT05984953?
The interventions under investigation include: statin (DRUG), evolocumab (DRUG).
Who is sponsoring clinical trial NCT05984953?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04276922 · 195 participants · NA
Creative Arts Program to Reduce Burnout in Healthcare Professionals
- NCT04829357 · 195 participants
Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
- NCT05054738 · 195 participants · NA
CRP and S&A for Inpatient Veterans
- NCT05561595 · 195 participants · NA
Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI